Infliximab and CT-P13 immunogenicity assessment in PLANETAS and PLANETRAS main and extension studies: utility of laboratory methods description

Ann Rheum Dis. 2016 Oct;75(10):e62. doi: 10.1136/annrheumdis-2016-210078. Epub 2016 Jul 11.

Authors

Francesca Meacci¹, Mariangela Manfredi¹, Maria Infantino¹, Valentina Grossi¹, Maurizio Benucci²

Affiliations

¹ Immunology and Allergology Laboratory, San Giovanni di Dio Hospital, Florence, Italy.
² Rheumatology Unit, San Giovanni di Dio Hospital, Florence, Italy.

PMID: 27401744
DOI: 10.1136/annrheumdis-2016-210078

No abstract available

Keywords: Ankylosing Spondylitis; Anti-TNF; Arthritis.

Publication types

Comparative Study
Letter

MeSH terms

Antibodies, Monoclonal / immunology
Antibodies, Monoclonal / therapeutic use*
Arthritis, Rheumatoid / drug therapy*
Arthritis, Rheumatoid / physiopathology
Biological Products / immunology
Biological Products / therapeutic use*
Biosimilar Pharmaceuticals / therapeutic use*
Cohort Studies
Drug Substitution
Female
Humans
Immunogenetic Phenomena
Infliximab / immunology
Infliximab / therapeutic use*
Male
Patient Safety
Spondylitis, Ankylosing / drug therapy*
Spondylitis, Ankylosing / immunology
Sweden
Treatment Outcome

Substances

Antibodies, Monoclonal
Biological Products
Biosimilar Pharmaceuticals
CT-P13
Infliximab